What does the Future Hold for Viral Gene Therapy?

• Hacein-Bey-Abina S , Le DeistF, De VillartayJPet al.: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med.346, 1185–1193 (2002).
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M , Hacein-BeyS, de Saint BasileGet al.: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science288, 669–672 (2000).
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S , von KalleC, SchmidtMet al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med.348, 255–256 (2003).
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S , Von KalleC, SchmidtMet al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science302, 415–429 (2003).
   PubMed Web of Science ®Google Scholar
• Aiuti A , SlavinS, AkerMet al.: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.Science296, 2410–2413 (2002).
   PubMed Web of Science ®Google Scholar
• Donsante A , MillerDG, LiYet al.: AAV vector integration sites in mouse hepatocellular carcinoma.Science317, 477 (2007).
   PubMed Web of Science ®Google Scholar
• Lok AS : Navigating the maze of hepatitis B treatments.Gastroenterology132, 1586–1594 (2007).
   PubMed Web of Science ®Google Scholar
• Yang PL , AlthageA, ChungJ, ChisariFV: Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection.Proc. Natl Acad. Sci. USA99, 13825–13830 (2002).
   PubMed Web of Science ®Google Scholar
• Giladi H , Ketzinel-GiladM, RivkinL, FeligY, NussbaumO, GalunE: Small interfering RNA inhibits hepatitis B virus replication in mice. Mol. Ther.8, 769–776 (2003).
   PubMed Web of Science ®Google Scholar
• Carmona S , ElyA, CrowtherCet al.: Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs.Mol. Ther.13, 411–421 (2006).
   PubMed Web of Science ®Google Scholar
• Shin D , KimSI, KimM, ParkM: Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice.Virus Res.119, 146–153 (2006).
   PubMed Web of Science ®Google Scholar
• Hung L , KumarV: Antisense regulation of expression and transactivation functions of the tumorigenic HBx and c-myc genes.Biochem. Biophys. Res. Commun.344, 293–299 (2006).
   PubMed Web of Science ®Google Scholar
• Welch PJ , TritzR, YeiS, BarberJ, YuM: Intracellular application of hairpin ribozyme genes against hepatitis B virus.Gene Ther.4, 736–743 (1997).
   PubMed Web of Science ®Google Scholar
• Kim YK , JunnE, ParkI, LeeY, KangC, AhnJK: Repression of hepatitis B virus X gene expression by hammerhead ribozymes.Biochem. Biophys. Res. Commun.257, 759–765 (1999).
   PubMed Web of Science ®Google Scholar
• zu Putlitz J , YuQ, BurkeJM, WandsJR: Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against hepatitis B virus.J. Virol.73, 5381–5387 (1999).
   PubMed Web of Science ®Google Scholar
• Darling JM , FriedMW: Optimizing treatment regimens in hepatitis C.Clin. Liver Dis.10, 835–850 (2006).
   PubMedGoogle Scholar
• Cornberg M , DeterdingK, MannsMP: Present and future therapy for hepatitis C virus.Expert Rev. Anti. Infect. Ther.4, 781–793 (2006).
   PubMedGoogle Scholar
• Blight KJ , KolykhalovAA, RiceCM: Efficient initiation of HCV RNA replication in cell culture.Science290, 1972–1974 (2000).
   PubMed Web of Science ®Google Scholar
• Lindenbach BD , EvansMJ, SyderAJet al.: Complete replication of hepatitis C virus in cell culture.Science309, 623–626 (2005).
   PubMed Web of Science ®Google Scholar
• Maeda N , WatanabeM, OkamotoSet al.: Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone.Liver Int.24, 259–267 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen J , BurdaMR, DandriM, RoglerCE: Transplantation of human hepatocytes in immunodeficient UPA mice: a model for the study of hepatitis B virus. Methods Mol. Med.96, 253–260 (2004).
   PubMedGoogle Scholar
• Mercer DF , SchillerDE, ElliottJFet al.: Hepatitis C virus replication in mice with chimeric human livers.Nat. Med.7, 927–933 (2001).
   PubMed Web of Science ®Google Scholar
• Randall G , GrakouiA, RiceCM: Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs.Proc. Natl Acad. Sci. USA100, 235–240 (2003).
   PubMed Web of Science ®Google Scholar
• Elazar M , LiuP, RiceCM, GlennJS: An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication.J. Virol.78, 11393–11400 (2004).
   PubMed Web of Science ®Google Scholar
• Ilan E , AraziJ, NussbaumOet al.: The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV.J. Infect Dis.185, 153–161 (2002).
   PubMed Web of Science ®Google Scholar
• Baltimore D : Gene therapy. Intracellular immunization.Nature335, 395–396 (1988).
   PubMed Web of Science ®Google Scholar
• Ranga U , WoffendinC, VermaSet al.: Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.Proc. Natl Acad. Sci. USA95, 1201–1206 (1998).
   PubMed Web of Science ®Google Scholar
• Woffendin C , RangaU, YangZ, XuL, NabelGJ: Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.Proc. Natl Acad. Sci. USA93, 2889–2894 (1996).
   PubMed Web of Science ®Google Scholar
• Levine BL , HumeauLM, BoyerJet al.: Gene transfer in humans using a conditionally replicating lentiviral vector.Proc. Natl Acad. Sci. USA103, 17372–17377 (2006).
   PubMed Web of Science ®Google Scholar
• Liu R , PaxtonWA, ChoeS, CeradiniD, MartinSR, HorukRet al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.Cell86, 367–377 (1996).
   PubMed Web of Science ®Google Scholar
• Castagna A , BiswasP, BerettaA, LazzarinA: The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development.Drugs65, 879–904 (2005).
   PubMed Web of Science ®Google Scholar
• Schols D : HIV coreceptor inhibitors as novel class of anti-HIV drugs.Antiviral Res.71, 216–226 (2006).
   PubMed Web of Science ®Google Scholar
• Biswas P , TambussiG, LazzarinA: Access denied? The status of coreceptor inhibition to counter HIV entry.Expert Opin Pharmacother.8, 923–933 (2007).
   PubMed Web of Science ®Google Scholar
• Qin XF , AnDS, ChenIS, BaltimoreD: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.Proc. Natl Acad. Sci. USA100, 183–188 (2003).
   PubMed Web of Science ®Google Scholar
• An DS , DonahueRE, KamataMet al.: Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.Proc. Natl Acad. Sci. USA104, 13110–13115 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen J : Building an HIV-proof immune system.Science317(5838), 612–614 (2007).
   Google Scholar

Websites

• Nature international weekly journal of science www.nature.com/nature/journal/v437/n7059/full/437601b.html
   Google Scholar
• Building an HIV-proof immune system. Science Magazine www.sciencemag.org/cgi/content/full/317/5838/612?etoc
   Google Scholar